BioCentury | Jan 9, 2021
Finance

Gracell looks to NASDAQ IPO to place it among CAR T leaders

...cell and gene therapy business well and will be long-term partners with us,” he said. Jeff Cranmer Gracell Biotechnologies Co. Ltd. bee2021 CAR...
BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...innovating around next-generation antibodies. A notable example is Gracell Biotechnologies Co. Ltd....
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...CFO to fill in for Michael McDonnell, who is joining Biogen Inc. (NASDAQ:BIIB) as CFO. Gracell Biotechnologies Co. Ltd....
...Holdings Inc. Replimune Group Inc. Cellectis S.A. Gamida Cell Ltd. Lakewood-Amedex Inc. Windtree Therapeutics Inc. Triplet Therapeutics Inc. Twist Bioscience Corp. Verrica Pharmaceuticals Inc. Gracell Biotechnologies Co. Ltd. Asklepios...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...No. 3014 ), a CD7-targeting CAR T cell for T cell acute lymphoblastic leukemia from Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

...first look at Phase I data from allogeneic CAR T therapy GC027 from Chinese biotech Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...No. DDT-02-04 and No. DDT-0301 ), along with an allogeneic CAR T cell therapy from Gracell Biotechnologies Co. Ltd....
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

...for FasT CAR-19 in B cell ALL Preliminary data showed that FasT CAR-19 (GC007F) from Gracell Biotechnologies Co. Ltd....
...RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Cancer Prevention Pharmaceuticals Inc. Exelixis Inc. Genentech Gracell Biotechnologies Co. Ltd. Progenics...
BioCentury | Jun 13, 2019
Emerging Company Profile

Gracell: Speeding up CAR T cells

...day, Gracell is lining up a set of therapies it could produce with the method. Gracell Biotechnologies Co. Ltd....
...years of runway and the company plans another round of financing next year. COMPANY PROFILE Gracell Biotechnologies Co. Ltd....
...William) Cao Patents: NA Companies and Institutions Mentioned Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 24, 2019
Clinical News

Gracell reports more potent CD19 CAR T using single-day manufacturing platform

...leukemia (ALL). The data reported Tuesday also showed that the therapy, dubbed CD19-F-CAR-T, was safe. Gracell Biotechnologies Co. Ltd....
...by Temasek (see "Gracell Raises $85M Series B to Advance Cell Therapies" ). Hongjiang Li, Staff Writer Gracell Biotechnologies Co. Ltd. CD19 CD19-F-CAR-T FasT...
BioCentury | Mar 2, 2019
Company News

Emerging company roundup: Anthos, Maze, Oyster Point

...Point Raises $93M series B” ). Meanwhile, Temasek led an $85 million B round for Gracell Biotechnologies Co. Ltd....
Items per page:
1 - 10 of 12
BioCentury | Jan 9, 2021
Finance

Gracell looks to NASDAQ IPO to place it among CAR T leaders

...cell and gene therapy business well and will be long-term partners with us,” he said. Jeff Cranmer Gracell Biotechnologies Co. Ltd. bee2021 CAR...
BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...innovating around next-generation antibodies. A notable example is Gracell Biotechnologies Co. Ltd....
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...CFO to fill in for Michael McDonnell, who is joining Biogen Inc. (NASDAQ:BIIB) as CFO. Gracell Biotechnologies Co. Ltd....
...Holdings Inc. Replimune Group Inc. Cellectis S.A. Gamida Cell Ltd. Lakewood-Amedex Inc. Windtree Therapeutics Inc. Triplet Therapeutics Inc. Twist Bioscience Corp. Verrica Pharmaceuticals Inc. Gracell Biotechnologies Co. Ltd. Asklepios...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...No. 3014 ), a CD7-targeting CAR T cell for T cell acute lymphoblastic leukemia from Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

...first look at Phase I data from allogeneic CAR T therapy GC027 from Chinese biotech Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...No. DDT-02-04 and No. DDT-0301 ), along with an allogeneic CAR T cell therapy from Gracell Biotechnologies Co. Ltd....
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

...for FasT CAR-19 in B cell ALL Preliminary data showed that FasT CAR-19 (GC007F) from Gracell Biotechnologies Co. Ltd....
...RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Cancer Prevention Pharmaceuticals Inc. Exelixis Inc. Genentech Gracell Biotechnologies Co. Ltd. Progenics...
BioCentury | Jun 13, 2019
Emerging Company Profile

Gracell: Speeding up CAR T cells

...day, Gracell is lining up a set of therapies it could produce with the method. Gracell Biotechnologies Co. Ltd....
...years of runway and the company plans another round of financing next year. COMPANY PROFILE Gracell Biotechnologies Co. Ltd....
...William) Cao Patents: NA Companies and Institutions Mentioned Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Gracell Biotechnologies Co. Ltd....
BioCentury | Apr 24, 2019
Clinical News

Gracell reports more potent CD19 CAR T using single-day manufacturing platform

...leukemia (ALL). The data reported Tuesday also showed that the therapy, dubbed CD19-F-CAR-T, was safe. Gracell Biotechnologies Co. Ltd....
...by Temasek (see "Gracell Raises $85M Series B to Advance Cell Therapies" ). Hongjiang Li, Staff Writer Gracell Biotechnologies Co. Ltd. CD19 CD19-F-CAR-T FasT...
BioCentury | Mar 2, 2019
Company News

Emerging company roundup: Anthos, Maze, Oyster Point

...Point Raises $93M series B” ). Meanwhile, Temasek led an $85 million B round for Gracell Biotechnologies Co. Ltd....
Items per page:
1 - 10 of 12